A5072174760- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Pharmaceutical studies and practices
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Radiopharmaceutical Chemistry and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Peptidase Inhibition and Analysis
- Glioma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Lung Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Gastrointestinal Tumor Research and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Mechanisms and Therapy
- IL-33, ST2, and ILC Pathways
Bashkir State Medical University
2017-2025
Mother Hospital
2020-2025
Republican Oncological Clinical Dispensary
2014-2022
Ministry of Health
2021
Ministry of Health of the Russian Federation
2019-2021
Academy of Sciences of the Republic of Bashkortostan
2013
McGill University
2011
Georgetown University
2011
Georgetown University Medical Center
2011
Instituto Nacional de Cancerología
2011
BackgroundProlgolimab is an IgG1 anti–PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed efficacy and safety of two dosing regimens prolgolimab in patients with advanced melanoma a multicenter open-label parallel-arm phase II trial (MIRACULUM). present final analysis after 1 year follow-up additional results from 2 years follow-up.MethodsPatients cutaneous or non-cutaneous melanoma, including stable brain metastasis, without...
Aim. To study the reasons for prescribing antitumor drugs (ATDs) beyond registered indications (BRIs) in real clinical practice. Materials and methods. The was conducted at Tula Regional Clinical Oncology Center. For 6 months of 2019, information analyzed on 919 completed cases treatment 201 patients over age 18 who received drug therapy morphologically verified solid malignant neoplasms inpatient department medical organization using a regional system. Completed with ATDs were copied BRIs...
Background . The major candidate genes for ovarian cancer (BRCA1/2) explain no more than 15–20 % of cases; therefore it is important to focus on the search new molecular genetic markers. aim study was analyze association rs11549465/HIF1A, rs3025039/VEGFA, and rs2146323/VEGFA polymorphic variants with risk developing in women from Republic Bashkortostan. Material methods Our research included DNA samples (n=205) without at time blood sampling (n=259) Genotyping carried out using Real Time PCR...
Background and objective — Gastric cancer (GC) is one of the most common cancers worldwide with a high mortality rate. Hereditary predisposition to GC still not fully understood. The this study was compare prevalence mutations in BRCA1 (c.68_69delAG, c.4035delA, c.5266dupC, c.3700_3704delGTAAA, c.3756_3759delGTCT, c.181T>G, c.1961delA), BRCA2 (c.5946delT), CHEK2 (c.1100delC, c.115+1G>A) NBS1 (c.657_661delGTTTT) genes patients healthy donors from Volga-Ural region Russia. Methods...
Neurologic symptoms caused by drug antitumor therapy remain a problem. The severity and frequency of development this type complications depend on the group, dose, duration use. Effective treatment requires proper approach to diagnosis toxic reactions. Therapy neurologic during should be based personalized due difference in mechanisms degree toxicity for each particular patient.Literature data main groups neurotoxic drugs, their action neurological administration are reviewed.
ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy quality of life.
Genome instability – the increased tendency of acquiring mutations in genome and ability a cell to tolerate high mutation burden - is one drivers cancer. results from many causes including defects DNA repair systems. Previously, it has been shown that germline pathogenic Mismatch Repair (MMR) pathway cause cancer-predisposing Lynch Syndrome. We proposed Syndrome-related (LS-mutations) are associated with breast cancer (BC). In this study, we performed Targeted Next-Generation Sequencing MMR...
Lung cancer has the highest morbidity rate among all malignant tumors in men and mortality women Russia. In total, 49 145 new cases of lung were registered (diagnosed) Russia 2019. The majority are related to exogenic carcinogens mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations updated strategies including adjuvant anti-PD-L1 atezolizumab following completion chemotherapy...
88 Background: Advanced gastric cancer (GC) is an incurable disease. HER2 overexpression has been reportedin 6%–35% of and gastroesophageal tumors, whereas the EGFR upregulated in about 18%–28%. Clinical studies confirm that targeting combination with chemotherapy effective strategy, achieving a median survival ∼13.5 mos. Lapatinib, dual tyrosine kinase inhibitor EGFR, inhibits tumor growth modulates expression fluoropyrimidine-targeting genes. LPT109747 international, multicenter phase II...
An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to determine the association of lapatinib-induced fluoropyrimidine gene changes with efficacy lapatinib plus capecitabine as first-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma independent tumor HER2 status. Tumor biopsies obtained before and after 7-day (1,250 mg) analyze in expression, followed by a 14-day course (1,000 mg/m(2) twice daily, 14/21 days) 1,250 mg daily....
Gastric cancer (GC) is one of the most common types in world with a high mortality rate. Hereditary predisposition for GC not fully elucidated so far. The aim this study was identification possible new candidate genes, associated increased risk gastric development. Whole exome sequencing (WES) performed on 18 DNA samples from adenocarcinoma specimens and non-tumor-bearing healthy stomach tissue same patient. Three pathogenic variants were identified: c.1320+1G>A CDH1 gene...
удалить
Значительное количество злокачественных новообразований яичников являются наследственными (до 30% всех возникают в результате высокой генетической предрасположенности). Известно, по меньшей мере, 16 генов-кандидатов наследственного рака (РЯ), а с внедрением и широким применением полногеномного секвенирования растет число генов генетических вариантов, потенциально вовлеченных патогенез семейных форм заболевания, хотя вклад этих развитие РЯ еще предстоит доказать. Обнаружение специфических...
.
20 Background: The results of the 5-year overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) has been reported rarely. aim RENSUR5 registry study was to obtain real-world data on use therapies mRCC and assess OS Russian population. Methods: Patients were retrospectively identified at 11 cancer centers different regions Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St.Petersburg, Ufa). included if diagnosed from...
Background: Defects in DNA damage recognition and repair has been implicated hereditary breast cancer (BC). Several studies demonstrated, that Fanconi Anemia (FA) associated genes-coding proteins products of BRCA1/2 genes cooperate a pathway which is required for resistance to interstrand crosslinks. Our aim was analyze nucleotide variants FA predisposing with an increased risk cancers. Methods: Targeted NGS performed cohort 630 BC patients strong evidence background cancer. The...
Purpose : To evaluate the proportion of BRCA1 / 2 mutations in patients with serous and endometrioid cancer ovary, fallopian tube, peritoneum Russia, to percentage germinal somatic mutations, identify spectrum genes, clinical morphological features BRCA-associated ovarian (OC). Patients methods The study enrolled 18 years older newly diagnosed peritoneum. Biological material (blood, tumor tissue) was collected, followed by molecular genetic analysis. method detecting blood were:...
Safety is recognized as a crucial issue of off-label use anticancer drugs. The potential benefits such prescriptions in oncology are associated with prevailing the expected clinical over risks complications. However, certain situations uncertain benefit/risk ratio, an drugs may threaten life and health patient. present paper explores safety drug therapy real practice. Health care routine practice given particular emphasis on systematic recording careful monitoring adverse events medicinal...
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. approval studies MONALEESA-2 7 demonstrated the efficacy safety ribociclib aromatase as first-line post- premenopausal patients. In Phase lllb CompLEEment-1 study, same regimen was evaluated an extended patient population terms both efficacy. article presents analysis data from subgroup...